Lorlatinib - PF-06463922 | Reagan-Udall Foundation

Brief Summary

Lorlatinib expanded access program

Status

Approved for marketing

EA Type

Individual Patients

Interventions

Drug: Lorlatinib

Eligibility Criteria

Inclusion Criteria:

- Adult, Senior

Exclusion Criteria:

-

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: N/A

NCT Number

NCT03127618

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA